Haleon plc (NYSE:HLN) Shares Sold by Exencial Wealth Advisors LLC

Exencial Wealth Advisors LLC decreased its holdings in Haleon plc (NYSE:HLN) by 1.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,048,167 shares of the company’s stock after selling 17,434 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Haleon were worth $10,000,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. FMR LLC grew its holdings in Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after purchasing an additional 5,768,117 shares during the period. Wellington Management Group LLP grew its stake in shares of Haleon by 49.9% during the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock valued at $96,833,000 after buying an additional 3,046,841 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after buying an additional 1,026,939 shares during the last quarter. Natixis Advisors LLC raised its position in shares of Haleon by 142.5% in the 3rd quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after buying an additional 866,070 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company’s stock valued at $19,758,000 after acquiring an additional 475,934 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Up 4.0 %

Shares of HLN opened at $10.59 on Tuesday. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The stock’s 50-day moving average is $9.59 and its two-hundred day moving average is $9.84. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The stock has a market cap of $47.94 billion, a PE ratio of 31.15, a P/E/G ratio of 2.82 and a beta of 0.28.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Equities analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This represents a yield of 1.6%. This is a positive change from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.